Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Cantor Global Healthcare Conference
Fireside Chat
September 3, 2025, at 2:10 pm ET

H.C.Wainwright 27th Annual Global Investment Conference
Presentation
September 9, 2025, at 2:30 pm ET

Stifel 2025 Virtual Immunology and Inflammation Forum
Fireside Chat
September 15, 2025, at 11:00 am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.¹ It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune mediated inflammatory diseases.^1-3

References: ¹Dinarello CA. Immunol Rev. 2018;281(1):8-27. ²Kany S et al. Int J Mol Sci. 2019;20(23):6008. ³Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
[email protected] 
410-803-6793

or

Meru Advisors
Lauren Glaser
[email protected] 

You May Also Be Interested In

• Berkeys Plumbing, A/C & Electrical Launches 2026 DFW Home Comfort & Energy Savings Report for North Texas Homeowners
• Raymond James Financial Declares Quarterly Dividend on Common Stock
• Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients